Biotech Values

[DewDiligence]

VRBPAC recommends JN.1 target for fall COVID vaccines:

https://thehill.com/policy/healthcare/4706149-fda-panel-picks-jn-1-subvariant-for-fall-covid-vaccines/

The expert advisory panel for the Food and Drug Administration (FDA) unanimously voted Wednesday in favor of selecting the JN.1 COVID-19 subvariant to be targeted by the next round of COVID-19 vaccines this fall.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked if it would recommended a monovalent vaccine that targets the JN.1 omicron subvariant for the 2024-2024 COVID vaccines. All 16 voting members voted in favor of selecting this lineage for the fall.

This decision is positive for NVAX insofar as NVAX is already manufacturing a JN.1 vaccine and it wouldn’t have been able to change strains in time for the 2024 fall vaccination season.